One hundred and fifty strains of anaerobic bacteria including 45 bacteroides, 19 fusobacteria, 41 cocci, 34 clostridia, and 11 Gram-positive non-sporeforming rods were tested by agar dilution for their susceptibilities to cefoxitin, cefuroxime, latamoxef (moxalactam), penicillin G, chloramphenicol, clindamycin, metronidazole and Sch 34343. Excluding the 34 clostridia, 115 of the 116 remaining strains were inhibited by less than or equal to 1 mg/l of Sch 34343. One isolate of Bacteroides fragilis required 32 mg/l for inhibition. All of the 34 clostridia were inhibited by less than or equal to 8 mg/l of Sch 34343: 14 isolates of Clostridium difficile had an MIC50 and an MIC90 of 4 mg/l, whereas the remaining 20 species of clostridia had an MIC50 of 0.125 mg/l and an MIC90 of 2 mg/l. On a weight basis, Sch 34343 was generally more active than any of the seven other antimicrobial agents tested.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/jac/15.suppl_c.177 | DOI Listing |
J Bacteriol
July 1992
Department of Chemistry, Bose Institute, Calcutta, India.
Penicillin-binding proteins (PBPs), although characterized from several organisms, have so far not been studied in mycobacteria. The present study is the first characterization of a PBP from Mycobacterium smegmatis. The PBP was purified by solubilization of the membranes with Triton X-100 and successive chromatography of the solubilized proteins on ampicillin-linked CH Sepharose 4B and DE-52.
View Article and Find Full Text PDFAntimicrob Agents Chemother
May 1990
Massachusetts General Hospital, Boston 02114.
Seven extended-spectrum beta-lactamases related to TEM and four enzymes derived from SHV-1 were transferred to a common Escherichia coli host so that the activity of a variety of beta-lactams could be tested in a uniform genetic environment. For most derivatives, penicillinase activity was 10% or less than that of strains making TEM-1, TEM-2, or SHV-1 beta-lactamase, suggesting that reduced catalytic efficiency accompanied the broader substrate spectrum. Despite this deficit, resistance to aztreonam, carumonam, cefdinir, cefepime, cefixime, cefmenoxime, cefotaxime, cefotiam, cefpirome, cefpodoxime, ceftazidime, ceftibuten, ceftizoxime, ceftriaxone, cefuroxime, and E1040 was enhanced.
View Article and Find Full Text PDFAntimicrob Agents Chemother
January 1990
Department of Microbiology and Immunology, University of California, Berkeley 94720.
The outer membrane of imipenem-resistant mutants of Pseudomonas aeruginosa with decreased permeability to imipenem was shown by Western (immuno-) blotting to contain protein D1 and to lack protein D2. Protein D2 was purified and was shown to allow the permeation of imipenem at a rate higher than expected from its molecular weight. Spontaneous imipenem-resistant mutants of P.
View Article and Find Full Text PDFJ Antimicrob Chemother
November 1989
Department of Medical Specialities, University of Texas M. D. Anderson Cancer Center, Houston 77030.
The in-vitro susceptibility of Mycobacterium avium complex isolates, obtained from immunosuppressed patients with and without the Acquired Immunodeficiency Syndrome (AIDS), to various antimicrobial agents was determined. Amikacin, the 4-quinolone compounds--ciprofloxacin, temafloxacin and PD 117558--and the penem SCH 34343 were active against most of the isolates. In-vitro synergism using selected antimicrobial combinations could not be demonstrated.
View Article and Find Full Text PDFJ Antimicrob Chemother
March 1989
Clinical Microbiology Institute, Tualatin, Oregon 97062.
The in-vitro activities of two penems (FCE 22101 and SCH 34343) were compared to those of a carbapenem (imipenem), a monobactam (aztreonam) and three cephalosporins (cefoperazone, ceftazidime, and cefotaxime). FCE 22101 displayed a broad spectrum of antibacterial activity against both Gram-negative and Gram-positive pathogens, including anaerobic bacteria. Imipenem and aztreonam, however, were a little more potent against susceptible species.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!